Literature DB >> 12876032

Imaging-guided percutaneous radiofrequency ablation of pulmonary metastatic nodules caused by hepatocellular carcinoma: preliminary experience.

Tae Sung Kim1, Hyo K Lim, Kyung Soo Lee, Young Cheol Yoon, Chin A Yi, Daehee Han.   

Abstract

OBJECTIVE: The purpose of our study was to evaluate the efficacy of imaging-guided percutaneous radiofrequency ablation of metastatic pulmonary nodules caused by hepatocellular carcinoma.
CONCLUSION: Percutaneous radiofrequency ablation is feasible and can be a promising method for the local control of metastatic pulmonary nodules caused by hepatocellular carcinoma, especially when they are limited in number.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876032     DOI: 10.2214/ajr.181.2.1810491

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Radiofrequency ablation of primary and metastatic lung tumors: preliminary experience with a single center device.

Authors:  D Laganà; G Carrafiello; M Mangini; L Boni; G Dionigi; M C Fusi; L Cinquepalmi; F Rovera; S Cuffari; C Fugazzola
Journal:  Surg Endosc       Date:  2006-07-20       Impact factor: 4.584

2.  Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation.

Authors:  Shin Hwang; Yong-Hee Kim; Dong Kwan Kim; Chul-Soo Ahn; Deog-Bok Moon; Ki-Hun Kim; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Hyeong Ryul Kim; Gil-Chun Park; Jeong-Man Namgoong; Sam-Youl Yoon; Sung-Won Jung; Seung Il Park; Sung-Gyu Lee
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

3.  Tumour characteristics and therapeutic results after percutaneous radiofrequency ablation of secondary lung neoplasms.

Authors:  Didier Dequanter; Philippe Lothaire
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

Review 4.  [RFA of bone and soft tissue tumors].

Authors:  T F Jakobs; R T Hoffmann; C Vick; A Wallnöfer; M F Reiser; T K Helmberger
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.